Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2− advanced breast cancer in the randomized MONALEESA-2 trial
Titel:
Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2− advanced breast cancer in the randomized MONALEESA-2 trial
Auteur:
O’Shaughnessy, Joyce Petrakova, Katarina Sonke, Gabe S. Conte, Pierfranco Arteaga, Carlos L. Cameron, David A. Hart, Lowell L. Villanueva, Cristian Jakobsen, Erik Beck, Joseph T. Lindquist, Deborah Souami, Farida Mondal, Shoubhik Germa, Caroline Hortobagyi, Gabriel N.